Meeting
2023 ASCO Annual Meeting
Neoadjuvant therapy of HER2 directed conventional dendritic cell (DC1) intratumoral (IT) therapy plus weekly paclitaxel, trastuzumab, and pertuzumab in patients with HER-2 positive breast cancer: NATASHA trial.
Authors
Hyo S. Han
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Hyo S. Han , Ricardo L Costa , Avan J. Armaghani , Susan Hoover , John Kiluk , Marie Catherine Lee , Hatem Hussein Soliman , Hung T. Khong , Loretta S. Loftus , Qianxing Mo , Jennifer A Childress , Edith Abraham , Kaitlin Hendrix , Amy Aldrich , Marina Sehovic , Zena Jameel , Shannon Falcon , Robert J Weinfurtner , Aixa Elena Soyano Muller , Brian J. Czerniecki
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT05325632
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 596)
DOI
10.1200/JCO.2023.41.16_suppl.596
Abstract #
596
Poster Bd #
426
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phase 1b study of ONT‑380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in third line + treatment of HER2+ metastatic breast cancer (MBC).
First Author: Erika Paige Hamilton
First Author: Nicholas Patrick McAndrew
Poster
2022 ASCO Annual Meeting
Combined assessment of metabolic response and tumor infiltrating lymphocytes as a predictor of outcomes following neoadjuvant therapy for HER2-positive breast cancer: Results from the randomized PREDIX HER2 trial.
First Author: Alexios Matikas
Poster
2021 ASCO Annual Meeting
Phase II prospective open label study of neoadjuvant pertuzumab, trastuzumab, and nab-paclitaxel in patients with HER-2 positive advanced breast cancer.
First Author: Sayeh Moazami Lavasani